Breast cancer metastasizing to the stomach mimicking primary gastric cancer: A case report

Kwangil Yim, Sang Mi Ro, Jieun Lee

Kwangil Yim, Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea

Sang Mi Ro, Jieun Lee, Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea

Jieun Lee, Cancer Research Institute, the Catholic University of Korea, Seoul 06591, South Korea

Author contributions: Yim K reviewed the pathologic findings and wrote the manuscript; Ro SM accessed patient information and edited the manuscript; Lee J designed, reviewed and wrote the manuscript.

Institutional review board statement: This case report was approved by the Institutional Review Board at the Seoul St. Mary’s Hospital (KC16ZISE0802).

Informed consent statement: Approved by the Institutional Review Board standards at the Seoul St. Mary's Hospital, the informed consent was omitted.

Conflict-of-interest statement: All authors have no personal, financial, or other conflicts of interest to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Received: November 24, 2016
Peer-review started: November 26, 2016
First decision: January 10, 2017
Revised: January 24, 2017
Accepted: March 2, 2017
Published online: March 28, 2017

Abstract

Breast cancer with stomach metastasis rare with an incidence of 1% or less among metastatic breast cancer patients. We experienced a case of breast cancer metastasizing to the stomach in 65-year-old female patient. She experienced dyspepsia and poor oral intake before visiting the clinic. Diffuse infiltration with nodular mucosal thickening of the stomach wall was observed, suggesting advanced gastric cancer based on gross endoscopic finding. Spread of poorly cohesive tumor cells in the gastric mucosa observed upon hematoxylin and eosin stain resembled signet ring cell carcinoma, but diffuse positive staining for GATA3 in immunohistochemical stain allowed for a conclusive diagnosis of breast cancer metastasizing to the stomach. Based on the final diagnosis, systemic chemotherapy was administered instead of primary surgical resection. After 2 cycles of docetaxel administration, she showed a partial response based on abdominal computed tomography scan. This case is an unusual presentation of breast cancer metastasizing to the gastrointestinal tract.

Key words: Gastric cancer; Breast cancer; Metastasis; Immunohistochemical stain; GATA3; GCDFP-15

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This case report describes a patient who was clinically diagnosed as advanced gastric cancer,
but final pathological confirm diagnosis was to be breast cancer with gastric metastasis. Patient received systemic chemotherapy and is currently on partial response state at present.

Yim K, Ro SM, Lee J. Breast cancer metastasizing to the stomach mimicking primary gastric cancer: A case report. World J Gastroenterol 2017; 23(12): 2251-2257. Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i12/2251.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i12.2251

INTRODUCTION
Breast cancer commonly metastasizes to bone, lung, liver, and brain, but metastasis to the gastrointestinal tract is rare[1,2]. In Korea, fewer than 10 cases of breast cancer metastasizing to the gastrointestinal tract have been reported[3]. Breast cancer with gastrointestinal metastasis requires systemic chemotherapy. However, if breast cancer with gastrointestinal metastasis is misdiagnosed as a primary gastrointestinal cancer, unnecessary surgical resection may take over place. Herein, the authors present a case of breast cancer metastasizing to the stomach, initially suspected to be primary gastric cancer. This patient was successfully treated with systemic chemotherapy.

CASE REPORT
A 65-year-old female patient was referred to the oncology department for evaluation of indigestion and epigastric discomfort. She had been previously diagnosed with breast cancer, treated with modified radical mastectomy (invasive lobular carcinoma, pT2N3MO), adjuvant chemotherapy (cyclophosphamide, methotrexate, 5-FU) and adjuvant radiation. Two years after surgery, she experienced cancer recurrence with bone metastasis and received an aromatase inhibitor (letrozole) as treatment for another 2 years. At the time she visited the oncology department, she was currently on aromatase inhibitor (letrozole). Other than breast cancer, she had no other medical history. Her last endoscopy was performed 2 years ago, with no specific findings.

Initial white blood cell (WBC) counts, hemoglobin level and hematocrit were 4790 cell/mm³ (neutrophil count 82%, lymphocytes count 25.8%), 13.1 g/dL (normal range 13.0-18.0 g/dL), and 369000/mm³ (normal range 150000-450000/mm³). Other laboratory findings including those of blood chemistry and urine analysis were in the normal range. Serum carcinoembryonic antigen level was increased up to 23.25 ng/dL.

Endoscopy revealed diffuse infiltration with nodular mucosal thickening of the stomach wall, involving the lower two-thirds of the stomach body (Figure 1). Based on endoscopy, endoscopic ultrasound (Figure 2A) and abdominal CT scan (Figure 2B), advanced gastric cancer (cT3N1MO) was suspected. Hematoxylin and eosin (H&E) staining of the endoscopic biopsy revealed poorly cohesive tumor cells spreading into the gastric mucosa, suggesting signet ring cell carcinoma. However, no intracytoplasmic mucin was found in the tumor cells, with scant to moderate pinkish cytoplasm.

NORMAL stomach glandular tissue was found in the biopsy specimen, with no cancer cells connected to the glandular structure (Figure 3A and B). These findings were not consistent with typical gastric signet ring cell carcinoma. Because the patient was diagnosed with invasive lobular carcinoma, archival breast tumor tissue was re-evaluated for comparison. Breast tissue pathology showed a similar appearance to the endoscopic biopsy specimen, such as a de-cohesive pattern with cells arranged in an Indian file pattern, and a centrally located enlarged nucleus (Figure 3C). In the immunohistochemical (IHC) test, the tumor cells showed diffuse strong nuclear staining for GATA3 binding protein (GATA3) (Figure 3D). IHC results of gross cystic disease fluid protein-15 (GCDFP-15) (Figure 3E), E-cadherin (Figure 3F), estrogen receptor (ER, Figure 3G) and progesterone receptor (PR, Figure 3H) were negative. HER-2 IHC staining showed weak membranous staining consistent with equivocal (+2) positivity (Figure 3I). Silver in situ hybridization (SISH) for HER-2 gene was performed, and the dual-probe HER2/Chr17 ratio was 3.2 (161/51), consistent with HER-2 amplification (Figure 3J).

Based on the pathologic findings, breast cancer metastasizing to the stomach was diagnosed. The stomach metastasis developed 4 years after surgery and 2 years after the initiation of an aromatase inhibitor use. As systemic treatment, docetaxel combined with trastuzumab was considered but trastuzumab was not available due to insurance guidelines. Docetaxel (75 mg/m² intravenously [I.V.], day 1) was administered every 3 wk. After 2 cycles of systemic chemotherapy, follow up abdominal CT scans showed decreased stomach wall thickness, and perigastric lymph nodes showed a partial response (PR) based on the Response Evaluation Criteria in Solid Tumors (Figure 4). During 2 cycles of systemic chemotherapy, the patient’s symptoms of indigestion and epigastric discomfort regressed. Currently, the patient is in persistent PR state and 6 cycles of docetaxel have been administered.

DISCUSSION
Cancer metastasizing to the gastrointestinal (GI) tract is reported to be rare, but breast cancer is the second most common cancer metastasizing to the GI tract after lung cancer[2,4]. However, the incidence of breast cancer with GI tract metastasis is reported to be 1% or lower[5,6]. Invasive lobular carcinoma tends to metastasize to the GI tract more frequently compared to invasive ductal carcinoma[7]. The most
common metastatic sites in the GI tract are the colon and rectum, stomach, small intestine and esophagus, in that order\textsuperscript{[4]}. In Korea, 7 cases of breast cancers metastasizing to the GI tract have been reported, with 5 cases of breast cancer with gastric metastases and 2 cases of synchronous stomach and colorectal metastases\textsuperscript{[3]}. The clinical characteristics of the previous cited cases are summarized in Table 1 \textsuperscript{[2,3,8-19]}.

Most breast cancer patients with gastric metastasis present with GI symptoms\textsuperscript{[3,16]}, similar to primary gastric cancer. In our case, the patient complained of indigestion, early satiety, and weight loss. Endoscopy with sufficient mucosal biopsy is mandatory for the diagnosis. Diffuse infiltration of the gastric wall with linitis plastica formation may be found\textsuperscript{[2]}, but approximately 50\% of patients may have shallow mucosal lesion indistinguishable from benign gastric mucosal lesions\textsuperscript{[20]}. Our patient showed extensive nodular mucosal thickening with a thickened gastric fold, with a primary suspicion of advanced gastric cancer.

Pathologic findings of breast cancer metastasizing to the stomach are morphologically similar to poorly cohesive gastric carcinoma, especially in invasive lobular carcinoma\textsuperscript{[21,22]}. However, some morphological differences are present. In metastatic mammary carcinoma, sialomucin is present in the intracytoplasmic lumina with a central location of the nucleus. In contrast, primary gastric signet ring cell carcinoma contains clear intracytoplasmic acid mucin.
Figure 3  Pathologic features of endoscopic biopsy specimen. Discohesive tumor cells are infiltrated in the stroma of the stomach mucosal tissue (HE × 40, A). Tumor cells show enlarged centrally located nucleus without intracytoplasmic clear mucin. The tumor cells had no connection to the remained normal gastric mucosal tissue (HE × 400, B). Previous breast cancer pathology was reviewed (C). Discohesive tumor cells were arranged in indian file. The tumor cells had enlarged centrally located nucleus without intracytoplasmic mucin (HE × 400, C). Immunohistochemical stains and molecular test of tumor was done (D-J). Diffuse strong nucleus expression of GATA3 was observed (GATA3 × 400, D). Focal, less than one percentage cytoplasmic expression of GCDFP was detected (GCDFP × 400, E). Negative stain for E-cadherin (E-cadherin × 400, F). Negative stains for ER and PR (ER × 400, PR × 400, G, H). Immunohistochemical stain for HER-2 was equivocal (HER-2 × 400, I). Silver in situ hybridization (SISH) for determination of HER2 gene status. Occasional HER2 gene amplified cells were noted in the mixture with normal HER2 gene expressing cells (SISH × 1000, J).
Figure 4  Response evaluation after 2 cycles of docetaxel chemotherapy (A, B). Abdominal CT scan shows decreased perigastric lymph nodes (arrows) and gastric mucosal thickening (arrowheads).

Table 1  Clinical characteristics of representative gastric metastasis of breast cancer

| Ref.          | Age | Duration after initial diagnosis | Clinical presentation          | Endoscopy                  | Pathology     | IHC         | Surgery | Treatment | Other metastasis site | Overall survival |
|---------------|-----|---------------------------------|-------------------------------|----------------------------|---------------|-------------|---------|-----------|----------------------|------------------|
| Our case      | 65  | 4                               | Epigastric discomfort         | Diffuse infiltrative mucosal lesion | ILC           | neg neg pos | No      | Bone      | -                    | -                |
| Pera et al[18] | 45  | 7                               | Epigastric pain, heartburn    | Polyp at antrum wall          | ILC           | pos pos -   | Subtotal gastrectomy | H         | -                    | -                |
|                | 51  | 3                               | No symptom                    | Erosion of gastric wall       | ILC           | neg neg neg | Total gastrectomy | No C,R    | Brain, bone, pleura | -                |
| Jones et al[2] | 61  | 6.9                             | Dysphagia, weight loss, nausea| Elevated mucosal lesion       | ILC           | pos pos neg | No      | C         | Liver, bone, pleura | -                |
| Eo et al[18]  | 48  | 9                               | Nausea anorexia               | Mucosal thickening            | IDC           | pos pos neg | No      | C         | -                    | 5.3              |
|                | 70  | 1                               | Diarrhea, constipation, diarrhea | Mucosal thickening         | ILC           | pos neg neg | No      | H         | Lung, rectum            | -                |
|                | 42  | 5                               | Epigastric pain               | Mucosal erosion              | ILC           | pos pos neg | No      | C         | -                    | -                |
|                | 54  | 6                               | Epigastric pain               | Mucosal erosion              | ILC           | pos pos neg | No      | C, H      | Liver, bone, peritoneum, Bone | 5.3              |
|                | 54  | 3                               | Epigastric pain vomiting      | Increased serum CEA, CA15-3  | IDC           | pos pos pos | No      | C         | Bone                  | -                |
| Geredeli et al [9] | 47  | 3                               | Abdominal pain with weight loss | Polypoid infiltration        | ILC           | neg neg neg | Subtotal gastrectomy | C         | Bone                  | -                |
| Buka et al[10] | 58  | 1.2                             | Abdominal pain with weight loss | Mucosal infiltration         | ILC           | pos pos neg | Total gastrectomy | C, R      | Colon, pleura          | 7.2              |
| Lee et al[11] | 48  | 5.7                             | Melena                        | Mucosal erosion              | -             | - - - -   | C       | Bone      | Liver                  | -                |
| Yim et al[12] | 48  | Initial diagnosis               | Epigastric discomfort         | Mucosal erosion              | ILC           | neg neg -  | No      | C         | Bone                  | -                |
| Jeon et al[13] | 49  | 5                               | Melena                        | Mucosal erosion              | IDC           | pos neg   | No      | C         | Bone                  | -                |
| Kim et al[14] | 53  | 10                              | Dyspepsia, lower abdominal pain, small caliper stool | Mucosal erosion | IDC           | neg neg -  | No      | C, H      | Kidney, ovary, colon, bone, pleural LN | 2.4              |
that pushes the nucleus to the periphery\textsuperscript{[21]}. In the present case, the nuclei of the tumor cells were located in the center, and there were no clear intracytoplasmic inclusions.

Also, IHC study is helpful for differential diagnosis. GCDFP-15 staining was traditionally used for differential diagnosis of mammary origin carcinoma. However, it shows relatively low sensitivity (55%-76\%) for detecting a breast origin cancer\textsuperscript{[23]}. Recently, GATA3 is widely known as a mammary cancer and urothelial cancer marker. GATA3 expression shows 100\% positivity in involving breast lobular carcinoma and 96\% positivity in breast ductal carcinoma. However, only 5\% of tumors are positive for GATA3 in gastric adenocarcinoma\textsuperscript{[24]}. In our case, although GCDFP-15 staining was negative, GATA3 showed diffuse strong nuclear positivity, consistent with a mammary origin of the carcinoma.

Metastatic breast cancer involving the stomach is treated with systemic agents such as cytotoxic chemotherapeutic agents or hormonal agents. Surgical resection of the stomach has a limited role in treatment, and does not affect the survival outcomes of patients presenting with gastric metastasis\textsuperscript{[41]}. However, surgical treatment may have a role in palliative treatment such as relieving obstructive symptoms.

Breast cancer patients have a superior survival outcome compared to other cancers, raising the possibility of a double primary cancer during the clinical course. However, metastasis of primary breast cancer must also be considered. In a breast cancer patient who complains of gastrointestinal symptoms, prompt endoscopy and biopsy are necessary for an accurate diagnosis. Sufficient pathologic review of gastric biopsy and previous breast specimens, with immunohistochemical examination is warranted. When metastasis of breast cancer to the stomach is suspected, appropriate systemic treatment is necessary for further treatment.

**COMMENTS**

**Case characteristics**

A 65-year-old female patient who was diagnosed as metastatic breast cancer visited the hospital for evaluation of epigastric discomfort.

**Clinical diagnosis**

Epigastric discomfort and indigestion.

**Differential diagnosis**

Gastric ulcer, primary gastric cancer showed be differentiated by endoscopic biopsy.

**Laboratory diagnosis**

Serum carcinoembryonic antigen was increased up to 23.25 ng/dL.

**Imaging diagnosis**

Endoscopy showed diffuse infiltration with nodular mucosal thickening of stomach wall.

**Pathological diagnosis**

Metastatic invasive lobular carcinoma to stomach was diagnosed by immunohistochemical stain.

**Treatment**

Docetaxel 150 mg/m\textsuperscript{2} intravenous, every 3 wk.

**Related reports**

Breast cancer rarely metastasize to gastrointestinal tract and should be diagnosed by careful review of the pathologic specimen. If patient have underlying breast cancer, metastatic breast cancer should be considered other than primary gastric cancer during the diagnosis.

**Term explanation**

GATA3 refers to GATA3 binding protein used for differential marker for diagnosis of breast cancer. Partial response (PR) means more than 30\% decrease in the sum of the longest diameters of target lesions during response evaluation.

**Experiences and lessons**

Early differential diagnosis of metastatic breast cancer to stomach is important for appropriate systemic chemotherapy and avoidance of unnecessary surgery.

**Peer-review**

This is generally an interesting and useful paper.

**REFERENCES**

1. Menuck LS, Amberg JR. Metastatic disease involving the stomach. *Am J Dig Dis* 1975; 20: 903-913 [PMID: 1190198 DOI: 10.1007/BF01070875]

2. Jones GE, Strausz DC, Forshaw MJ, Deere H, Mahedeva U, Mason RC. Breast cancer metastasis to the stomach may mimic primary gastric cancer: report of two cases and review of literature. *World J Surg Oncol* 2007; 5: 75 [PMID: 17620117 DOI: 10.1186/1477-7819-5-75]
Yim K et al. Breast cancer with stomach metastasis

10.1186/1477-7819-5-75

3 Yu HA, Kim EY, Seo MJ, Chung E, Cho MJ, Oh HJ, Jang JH, Park JC, Lee JU, Park SY. Stomach and Colon Metastasis from Breast Cancer. *Ewaha Med J* 2014; 37: 98-104 [DOI: 10.12771/ emj.2014.37.2.98ISSN]

4 McLemore EC, Pockaj BA, Reynolds C, Gray RJ, Hernandez JL, Grant CS, Donohue JH. Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis. *Ann Surg Oncol* 2005; 12: 866-894 [PMID: 16177864 DOI: 10.1245/ASO.2005.03.030]

5 Khaddim M. The effects of Pan and its ingredients on oral mucosa. *J Pak Med Assoc* 1977; 27: 353-356 [PMID: 413949 DOI: 10.4061/2011/413949]

6 Matsuda I, Matsubara N, Aoyama N, Hnamakana M, Yamagishi D, Kuno T, Tsukamoto K, Yamano T, Noda M, Ikeuchi H, Tomita N, Hirota S. Metastatic lobular carcinoma of the breast masquerading as a primary rectal cancer. *World J Surg Oncol* 2012; 10: 231 [PMID: 23114188 DOI: 10.1186/1477-7819-10-231]

7 Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood RA. Comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. *Br J Cancer* 1984; 50: 23-30 [PMID: 6331484]

8 Arranzoiz R, Papavasilious P, Dushkin H, Farma JM. Case report and literature review: Metastatic lobular carcinoma of the breast an unusual presentation. *Int J Surg Case Rep* 2011; 2: 301-305 [PMID: 22096760 DOI: 10.1016/j.jsrcr.2011.06.010]

9 Buka D, Dvóřák J, Richter I, Hadzi ND, Cyraný J. Gastric and Colorectal Metastases of Lobular Breast Carcinoma: A Case Report. *Acta Medica (Hradec Kralove)* 2016; 59: 18-21 [PMID: 27131352 DOI: 10.14712/18059694.2016.50]

10 Cheoi KS, Eum YO, Kim HS, Lee OJ, Lee KH. A case of stomach metastasis from breast cancer. *Korean J Med* 2006; 71: 567-572

11 Eo WK. Breast cancer metastasis to the stomach resembling early gastric cancer. *Cancer Res Treat* 2008; 40: 207-210 [PMID: 19688132 DOI: 10.4143/crt.2008.40.4.207]

12 Geredeli C, Dogru O, Omeroglu E, Yilmaz F, Cicekci F. Gastric Metastasis of Triple Negative Invasive Lobular Carcinoma. *Rare Tumors* 2015; 7: 576 [PMID: 26266010 DOI: 10.4081/ rt.2015.5764]

13 Hwang SY, Ryu DY, Park JH, Lee DW, Lee DH, Kim TO, Kim GH, Heo J, Kang DH, Song GA, Cho M, Park DY. [A case of gastric metastasis of breast carcinoma resembling early gastric cancer]. *Korean J Gastroenterol* 2005; 46: 481-484 [PMID: 16371724]

14 Jeon SH, Kwon TK, Kim SH, Kwon DY, Park KS. A case of gastric metastasis from breast carcinoma manifested by upper gastrointestinal bleeding. *Korean J Gastrointest Endosc* 2002; 24: 220-224

15 Kim DY, Van T, Kim TY, Heo DS, Bang YJ. Renal, gastric, and multiple intestinal metastases of invasive ductal carcinoma of breast. *Korean J Med* 2003; 65: S836-S840

16 Koike K, Kitahara K, Higaki M, Urata M, Yamazaki F, Noshito H. Clinicopathological features of gastric metastasis from breast cancer in three cases. *Breast Cancer* 2014; 21: 629-634 [PMID: 21779814 DOI: 10.1007/s12282-011-0284-3]

17 Lee SI, Moon YM, Kang JK, Park JH, Choi HJ, Kim BS, Kim TS. A case of gastric metastasis from breast cancer. *Korean J Gastroenterol* 1983; 15: 157-162

18 Pera M, Riera E, Lopez R, Viñolas N, Romagosa C, Miquel R. Metastatic carcinoma of the breast resembling early gastric carcinoma. *Mayo Clin Proc* 2001; 76: 205-207 [PMID: 11213310 DOI: 10.1016/S0025-6196(11)63129-7]

19 Yim J, Jin YM, Shim C, Park HB. Gastric metastasis of mammary signet ring cell carcinoma--a differential diagnosis with primary gastric signet ring cell carcinoma. *J Korean Med Sci* 1997; 12: 256-261 [PMID: 9250925 DOI: 10.3346/jkms.1997.12.3.256]

20 Lorimier G, Binelli C, Burtin P, Maillart P, Bertrand G, Verriele V, Fondrinier E. Metastatic gastric cancer arising from breast carcinoma: endoscopic ultrasonographic aspects. *Endoscopy* 1998; 30: 800-804 [DOI: 10.1055/s-2007-1001425]

21 Chu PG, Weiss LM. Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. *Am J Clin Pathol* 2004; 121: 884-892 [PMID: 15198362 DOI: 10.1309/ A09E-RYM6-R64N-ERDW]

22 Taal BG, Petersen H, Boot H. Clinical presentation, endoscopic features, and treatment of gastric metastases from breast carcinoma. *Cancer* 2000; 89: 2214-2221 [PMID: 11147591]

23 Honna N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ita Y, Akiyama F, Sakamoto G. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. *J Clin Oncol* 2008; 26: 3727-3734 [PMID: 18669459 DOI: 10.1200/JCO.2007.14.2968]

24 Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czupajewski P, Waźny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Zajacova J. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. *Am J Surg Pathol* 2014; 38: 13-22 [PMID: 24145643 DOI: 10.1097/PAS.0b013e3182a02188]

P- Reviewer: Thota PN, Serban ED S--Editor: Qi Y L- Editor: A E- Editor: Wang CH
